Compounded Semaglutide vs. Ozempic and Wegovy: What's Actually Different?
A factual, non-marketing comparison of two real categories of GLP-1 medication. We dispense compounded; we'll be straight with you about what that means and when it's the right choice.
The two categories explained
Brand-name FDA-approved GLP-1 drugs
This is Novo Nordisk's Ozempic (approved for type 2 diabetes), Wegovy (approved for chronic weight management), Eli Lilly's Mounjaro (type 2 diabetes), and Zepbound (chronic weight management). These are finished pharmaceutical products that have gone through full FDA review for safety, efficacy, and manufacturing standards. They're sold in pre-filled pens at standardized doses. Cash list prices in the U.S. as of 2026 are roughly $968/month (Ozempic) to $1,349/month (Wegovy and Zepbound).
Compounded GLP-1 medications
A compounded medication is one made by a licensed compounding pharmacy for an individual patient based on a physician's prescription. The active pharmaceutical ingredient — the same semaglutide or tirzepatide molecule — is sourced from FDA-registered facilities. The compounding pharmacy combines it with sterile diluent into a final injectable product. Each batch is mixed, tested, and dispensed under state pharmacy board oversight. Cash price at New Hope Weight Loss for compounded semaglutide is $499 for a 90-day supply ($166/month).
What's actually the same
- The active ingredient. Semaglutide is semaglutide. Tirzepatide is tirzepatide. Whether the molecule is in a Wegovy pen or a 5 mL vial from a compounding pharmacy, the chemistry is identical when sourced from a reputable manufacturer.
- The mechanism. GLP-1 receptor agonism, gastric emptying delay, hypothalamic appetite reduction, and reward-circuit modulation all happen the same way regardless of which finished product you're using.
- The clinical effect. Patients on properly dosed compounded semaglutide and patients on Wegovy follow similar weight-loss curves in our clinic — both seeing the steep early loss and the eventual plateau described in the GLP-1 trials.
What's actually different
| Dimension | Brand-name (Wegovy etc.) | Compounded |
|---|---|---|
| Regulatory status | FDA-approved finished drug | Patient-specific compound; pharmacy state-licensed; APIs FDA-registered |
| Manufacturer | Novo Nordisk / Eli Lilly | Licensed 503A compounding pharmacy |
| Form | Pre-filled pen, fixed doses | Vial + syringe; doses prescribed and titrated individually |
| Excipients | Standardized per FDA label | Vary by pharmacy; B6 / B12 combinations are common |
| Cash price (no insurance) | ~$1,349/mo (Wegovy) | $166/mo (NHWL semaglutide 3-mo plan) |
| Insurance coverage | Sometimes covered with PA | Generally not covered by insurance; HSA/FSA usually eligible |
| Supply | Subject to manufacturer shortage cycles | More consistently available during shortages |
| Counterfeit risk | Low when filled at a U.S. retail pharmacy | Low at reputable 503A; higher for offshore "peptide" vendors |
Why compounded exists at all
Compounding pharmacies have been part of U.S. medicine for over a century. Their core role is to fill gaps the standardized commercial drug supply doesn't: a child who needs a liquid version of an adult tablet, a patient with an allergy to a brand's preservative, a hospital making sterile preparations for the operating room. They're regulated under federal law (FD&C Act §503A) and individual state pharmacy boards.
For GLP-1 medications specifically, the FDA declared a shortage of brand-name semaglutide in 2022 and tirzepatide in 2023, which permitted 503A pharmacies to compound these molecules under federal exception. The shortage status of semaglutide was lifted in 2024 and tirzepatide in late 2024, and the FDA issued additional guidance on the legal pathways forward in 2025. Compounding for individual patients with documented clinical need continues under that updated framework.
What "503A pharmacy" means and why it matters
Not all compounding pharmacies are equal. The two regulatory categories worth knowing:
- 503A: traditional compounding pharmacies that dispense to individual patients with prescriptions. State-licensed and inspected. This is what reputable telehealth GLP-1 providers, including New Hope Weight Loss, use.
- 503B: outsourcing facilities that produce in larger batches under cGMP standards similar to drug manufacturing. Generally for hospitals and clinics; not for direct patient compounding.
Avoid: vendors selling "research peptides" online, anything labeled "not for human use," anything imported from overseas peptide marketplaces, or any practitioner who can't tell you the name and license status of the pharmacy filling the prescription. We tell every patient who fills our prescriptions and we'll write it on your invoice if you ask.
When brand-name is the right answer
We're a compounded-medication clinic and we'll still tell you to use brand-name when it's the right call:
- Your insurance covers Wegovy, Zepbound, Ozempic, or Mounjaro for your indication and your out-of-pocket is comparable.
- You have type 2 diabetes and your endocrinologist is managing your care with brand-name GLP-1.
- You're enrolled in a clinical trial of a specific brand-name product.
- You have a documented allergy or sensitivity to a compounding excipient.
- You travel internationally frequently and customs documentation for compounded medication is a hassle.
When compounded is a reasonable choice
- You don't have insurance coverage for brand-name and the $1,349/month cash price isn't realistic.
- You want a clearer dose-titration schedule that matches your physiology rather than the pen's fixed step doses.
- The brand-name product is in shortage in your area.
- You want a transparent, all-in price including physician supervision.
Red flags when shopping for compounded GLP-1 anywhere
- No physician consultation before prescription.
- Pharmacy name not disclosed.
- "Research peptide" or "not for human use" labeling.
- No batch number or lot information on the vial.
- No follow-up or dose-titration schedule.
- Marketing language implying equivalence to or replacement of brand-name drugs ("this is just like Ozempic," "the same as Wegovy"). Equivalence claims are not legally defensible and they're a marker of a careless vendor.
Frequently asked questions
Is compounded semaglutide the same as Ozempic or Wegovy?
No. They contain the same active ingredient (semaglutide), but the products are not legally the same. Brand-name products are FDA-approved finished drugs; compounded medications are made by licensed compounding pharmacies for individual patients. The regulatory pathway, manufacturing standard, and product profile differ.
Is compounded semaglutide FDA-approved?
Compounded medications themselves are not FDA-approved as finished products. The active ingredient is sourced from FDA-registered facilities, and 503A pharmacies are state-licensed and overseen by their state board of pharmacy. The legal framework for compounded GLP-1s during and after the brand-name shortage was updated by the FDA in 2024–2025.
Does compounded mean lower quality?
Not by definition. Quality depends on the specific compounding pharmacy. A reputable 503A pharmacy with sterile preparation, batch testing, and traceable APIs produces a high-quality product. Quality drops sharply with offshore peptide vendors. Always verify your physician sources from a state-licensed pharmacy.
Why is compounded semaglutide cheaper than Wegovy?
Brand-name carries Novo Nordisk's research, marketing, regulatory, and patent costs that a compounded product does not. Cash price for Wegovy is approximately $1,349/month; compounded semaglutide at New Hope Weight Loss starts at $166/month. The active ingredient is the same; the price difference reflects the regulatory and brand pathway.
Are there situations where I should use brand-name instead?
Yes — and we'll tell you when. If your insurance covers Wegovy, Ozempic, Mounjaro, or Zepbound for your condition, brand-name is usually the better path. If you have a known allergy to a compounding excipient, brand-name is the right choice. We help patients evaluate this honestly.
This article is informational only and not medical advice. Speak with a licensed physician before starting any GLP-1 therapy. Individual results vary. New Hope Weight Loss dispenses compounded semaglutide and compounded tirzepatide via state-licensed 503A pharmacies. We do not dispense Ozempic, Wegovy, Mounjaro, or Zepbound — those are brand-name FDA-approved medications manufactured by Novo Nordisk and Eli Lilly. Trade-name references in this article are for educational comparison only and do not imply equivalence, endorsement, or affiliation.